(Q43286135)

18 November 2017

title

Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. (English)

1 reference

18 November 2017

1 reference

1 reference

Kakil Ibrahim Rasul

1

1 reference

18 November 2017

David J Kerr

series ordinal

2

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Nature Reviews Clinical Oncology

18 November 2017

published in

1 reference

18 November 2017

volume

6

1 reference

18 November 2017

issue

9

1 reference

18 November 2017

page(s)

499-500

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

Thymic carcinoma: 30 cases at a single institution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.108

10.1038/NRCLINONC.2009.108

31 March 2020

Identifiers

DOI

1 reference

release_y4cbwnezb5ggfmw3q7mpxvx7cm

18 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y4cbwnezb5ggfmw3q7mpxvx7cm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference